Pharmacology Articles

About Authors:
V. KRISHNA KISHORE
M.Pharm, 2nd Sem (Pharmaceutics)
Roland Institute of  Pharmaceutical Sciences , Berhampur, Odisha.
Krishnakishorev58@gmail.com

1. Abstract:
Pharmacokinetics is currently defined as the study of the time course of drug absorption, distribution, metabolism, and excretion. Clinical pharmacokinetics is the application of pharmacokinetic principles to the safe and effective therapeutic management of drugs in an individual patient.
Primary goals of clinical pharmacokinetics include enhancing efficacy and decreasing toxicity of a patient's drug therapy. The development of strong correlations between drug concentrations and their pharmacologic responses has enabled clinicians to apply pharmacokinetic principles to actual patient situations.
A drug's effect is often related to its concentration at the site of action, so it would be useful to monitor this concentration. Receptor sites of drugs are generally inaccessible to our observations or are widely distributed in the body, and therefore direct measurement of drug concentrations at these sites is not practical. For example, the receptor sites for digoxin are believed to be within the myocardium, and we cannot directly sample drug concentration in this tissue. However, we can measure drug concentration in the blood or plasma, urine, saliva, and other easily sampled fluids.

About Authors:
Devendra Kumar¹,Pragya Seth²
Department of Pharmaceutical technology,
¹Sri Satya Sai collage of Pharmacy Bhopal,
²Lakshmi Narain College of Pharmacy, Bhopal
*guptadevendra15@gmail.com

Abstract
The present work describes the effect of methanolic extract of Prunus amygdalus (batsch.) on pylorus ligation and Ethanol-induced gastric ulcer models in Wistar rats. The present study provides a strong evidence of antiulcer activity of Prunus amygdalus extract against gastric lesions. The antiulcer activity is recognized by a reduction in acid-secretary parameters like total and free acidity, gastric volume and ulcer score suggesting that acid inhibition accelerates ulcer healing, thereby strengthening of mucosal barrier. In this present study it shows significant protection for Hexosamine in all treated groups in comparison to negative control group. Inthe LPO results it was observed that there was significance level difference in negative control group and all other group that indicates that lipid peroxides enzyme was higher in vehicle treated group. Ulcer score was determined by the counting of spots and severity of damage in stomach part by any moiety such as ethanol. Single drug treatment (200 mg/kg and 400mg/kg of P.A.E.) was effective up to a significant level (P<0.05) in compare to negative control group.Volume of gastric juice indicate the secretions of gastric fluid and it is higher in negative control group and all drug treated group was effective in relation to negative control group in significance level (P <0.05).

About Authors:
*Lavkesh A.Chandivade,  Vishal V.Bandre,  Nilesh M. Choudhary
Viva Institute of Pharmacy
Shirgaon ,Virar(E)
*lavkeshc@gmail.com

ABSTRACT:
BOTULINUM TOXIN is a neurotoxin that is made of a complex mixture of proteins containing botulinum neurotoxin and various non-toxic proteins.
The neurotoxin clostridium botulinum is a spore-forming gram positive anaerobic bacterium that is made up of light chain and a heavy chain linked by single disulphide bond. The non-toxic proteins include haemagglutinating proteins. The bacteria are considered harmful and life threatening and can lead to muscle paralysis or weakness. However Botulin toxin treatment is quite safe especially when used in small doses and injected directly to a specific area.

About Authors:
Mr. Satyanand Tyagi*, Patel Chirag J¹, Devesh Kaushik²
*President, Tyagi Pharmacy Association & Scientific Writer (Pharmacy), Chattarpur, New Delhi, India-110074.
Prof. Satyanand Tyagi is a life time member of various pharmacy professional bodies like IPA, APTI and IPGA. He has published various research papers and review articles. His academic work includes 60 Publications (50 Review Articles, 08 Research Articles and 02 Short Communications of Pharmaceutical, Medicinal and Clinical Importance, published in standard and reputed National and International Pharmacy journals; Out of 60 publications, 11 are International Publications).
He has published his papers almost in different specialization of Pharmacy field...His research topics of interest are neurodegenerative disorders, diabetes mellitus, cancer, rare genetic disorders, psycho-pharmacological agents as well as epilepsy.
¹Department of Pharmaceutics, Maharishi Arvind Institute of Pharmacy, Mansarovar, Jaipur, Rajasthan, India-302020.
²Territory Business Manager, Diabetes Division, Abbott Healthcare Private Limited, Okhla, New Delhi, India- 110020.
*sntyagi9@yahoo.com, +91-9871111375/9582025220

ABSTRACT:
A group of Australian researchers at the Garvan Institute in Sydney have conducted a study indicating how Grb10 protein plays a crucial role in increasing muscle mass during development. Growth factor receptor-bound protein 10 also known as insulin receptor-binding protein Grb-IR is a protein that in humans is encoded by the GRB10 gene. The product of this gene belongs to a small family of adapter proteins that are known to interact with a number of receptor tyrosine kinases and signaling molecules. This gene encodes a growth factor receptor-binding protein that interacts with insulin and insulin-like growth-factor receptors (e.g., IGF1R and IGF2R). Over expression of some isoforms of the encoded protein inhibits tyrosine kinase activity and results in growth suppression. This gene is imprinted in a highly isoform- and tissue-specific manner. Alternatively spliced transcript variants encoding different isoforms have been identified.Scientists have discovered a way to build bigger and stronger muscles without having to lift a finger.

About Authors:
Amardeep Sharma
Rathi Orthopaedic & research centre,
Ahmedabad, India
amardeep.sharma54@gmail.com
{ DOWNLOAD AS PDF }

ABSTRACT:-
The knowledge of breast cancer development and progression has grown in recent years and relatively development of novel therapeutic strategies, but for cancer mortalities in women breast cancer stands at 2^nd position as cause.
In U.S. Approximately 39970 women & 450 men in the U.S. will be diagnosed from the disease in 2011.^[1] Breast cancer is a hormone dependent disease.^[3] Breast cancer occurs when breast epithelial cells grows in abnormal way. HER2/neu, ER, PR, BRCA1, BRCA2 are the well known influencing factors responsible for breast cancer initiation. The major issues that limit the currently available breast cancer treatment are high cost, poor availability and resistance to chemotherapeutic agents. To overcome this problem researchers are working on several novel approaches i.e. “Novel drug targets & Novel target therapies”.
Since from past few years, mammogram is playing a huge role for decreasing incidence rate in developed countries. Breast cancer is adversely affecting the “quality of life” of patients and its impact has been increasing on the Social capital, population structure and economic growth. Need for novel anti breast cancer agent and novel early diagnosis technique is necessary to combat one of the most serious crises facing Human development.

About Authors:
Mr. Satyanand Tyagi*, Patel Chirag J¹, Asheesh Singh²
*President, Tyagi Pharmacy Association & Scientific Writer (pharmacy), Chattarpur, New Delhi, India-110074.
Prof. Satyanand Tyagi is a life time member of various pharmacy professional bodies like IPA, APTI and IPGA. He has published various research papers and review articles. His academic works include 52 Publications (44 Review Articles and 08 Research Articles of Pharmaceutical, Medicinal and Clinical Importance, published in standard and reputed National and International Pharmacy journals; Out of 52 publications, 11 are International Publications).
He has published his papers almost in different specialization of Pharmacy field...His research topics of interest are neurodegenerative disorders, diabetes mellitus, cancer, rare genetic disorders, psycho-pharmacological agents as well as epilepsy.
¹Department of Pharmaceutics, Maharishi Arvind Institute of Pharmacy, Mansarovar, Jaipur, Rajasthan, India-302020.
²Research Associate, Center for Research and Development, Ipca Laboratories Ltd Ratlam, Madhya Pradesh, India-457114.
*sntyagi9 @yahoo.com, +91-9871111375 / 9582025220

ABSTRACT:
Prior studies have suggested that depressed people with evidence of high inflammation are less likely to respond to traditional treatments for the disorder, including anti-depressant medications and psychotherapy. This study was designed to see whether blocking inflammation would be a useful treatment for either a wide range of people with difficult-to-treat depression or only those with high levels of inflammation. The study employed infliximab, one of the new biologic drugs used to treat autoimmune and inflammatory diseases such as rheumatoid arthritis and inflammatory bowel disease. A biologic drug copies the effects of substances naturally made by the body's immune system. In this case, the drug was an antibody that blocks tumour necrosis factor (TNF), a key molecule in inflammation that has been shown to be elevated in some depressed individuals. Study participants all had major depression and were moderately resistant to conventional antidepressant treatment. Each participant was assigned either to infliximab or to a non-active placebo treatment. When investigators looked at the results for the group as a whole, no significant differences were found in the improvement of depression symptoms between the drug and placebo groups. However, when the subjects with high inflammation were examined separately, they exhibited a much better response to infliximab than to placebo.

About Authors:
Mr. Satyanand Tyagi
President, Tyagi Pharmacy Association & Scientific Writer,
Chattarpur, New Delhi, India.
Prof. Satyanand Tyagi is a life time member of various pharmacy professional bodies like IPA, APTI and IPGA. He has published various research papers and review articles. His academic works include 50 Publications (42 Review Articles and 08 Research Articles of Pharmaceutical, Medicinal and Clinical Importance, published in standard and reputed National and International Pharmacy journals; Out of 50 publications, 11 are International Publications).
sntyagi9@yahoo.com, +91-9871111375 / 9582025220

ABSTRACT:
Diabetic nephropathy is one of the most serious complications related to diabetes, often leading to end-stage kidney disease. Purple corn grown in Peru and Chile is a relative of blue corn, which is readily available in the U.S. The maize is rich in anthocyanins (also known as flavonoids), which are reported to have anti-diabetic properties. Scientists from the Department of Food and Nutrition and Department of Biochemistry at Hallym University in Korea investigated the cellular and molecular activity of purple corn anthocyanins (PCA) to determine whether and how it affects the development of diabetic nephropathy (DN). Their findings suggest that PCA inhibits multiple pathways involved in the development of DN, which may help in developing therapies aimed at type 2 diabetes and kidney disease. The aim of present article is to provide in depth knowledge about Purple Corn, their clinical and biological utility as well as their role in treatments of type 2 diabetes and kidney disease. An attempt is also made to focus on compounds found in purple corn which may aid in developing future treatments for type 2 Diabetes as well as kidney disease.